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Abstract
Background: Osteoarthritis (OA) is one of the main causes of disability worldwide, especially in
persons >55 years of age. Currently, controversy remains about the best therapeutic alternative
for this disease when evaluated from a cost-effectiveness viewpoint. For Social Security Institutions
in developing countries, it is very important to assess what drugs may decrease the subsequent use
of medical care resources, considering their adverse events that are known to have a significant
increase in medical care costs of patients with OA. Three treatment alternatives were compared:
celecoxib (200 mg twice daily), non-selective NSAIDs (naproxen, 500 mg twice daily; diclofenac,
100 mg twice daily; and piroxicam, 20 mg/day) and acetaminophen, 1000 mg twice daily. The aim
of this study was to identify the most cost-effective first-choice pharmacological treatment for the
control of joint pain secondary to OA in patients treated at the Instituto Mexicano del Seguro
Social (IMSS).
Methods: A cost-effectiveness assessment was carried out. A systematic review of the literature
was performed to obtain transition probabilities. In order to evaluate analysis robustness, one-way
and probabilistic sensitivity analyses were conducted. Estimations were done for a 6-month period.
Results: Treatment demonstrating the best cost-effectiveness results [lowest cost-effectiveness
ratio $17.5 pesos/patient ($1.75 USD)] was celecoxib. According to the one-way sensitivity
analysis, celecoxib would need to markedly decrease its effectiveness in order for it to not be the
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optimal treatment option. In the probabilistic analysis, both in the construction of the acceptability
curves and in the estimation of net economic benefits, the most cost-effective option was
celecoxib.
Conclusion:  From a Mexican institutional perspective and probably in other Social Security
Institutions in similar developing countries, the most cost-effective option for treatment of knee
and/or hip OA would be celecoxib.
Background
Osteoarthritis (OA) is a progressive disorder characterized
by the destruction of joint cartilage and subchondral
bone, as well as changes in the synovium [1]. Worldwide,
it is one of the most important causes of disability. OA
ranks 4th as a disabling disease in women and ranks 8th
in men [1,2]. OA is the most frequent joint disease.
Because the knee is a weight-bearing joint, it is the most
affected; ~10% of the population suffering from knee OA
has disabling symptomatology [3].
The main objectives of OA pharmacotherapy are to
achieve an anti-inflammatory and analgesic effect [4,5].
Analgesic and anti-inflammatory properties of nonsteroi-
dal anti-inflammatory drugs (NSAIDs) are based on the
inhibition of the cyclooxygenase (COX) enzyme isoforms
[6]. Traditional NSAIDs inhibit both isoforms of the COX
enzyme responsible for the first step in the conversion of
arachidonic acid into a variety of prostaglandins, throm-
boxanes and leukotrienes in the body [7]. Anti-inflamma-
tion and pain decrease with the effects of NSAIDs,
resulting from the inhibition of COX-2-mediated prostag-
landin synthesis at the site of the damaged tissue, whereas
gastrointestinal (GI) complications are due to the inhibi-
tion of COX-1-mediated prostaglandin synthesis in the GI
mucosa. Therefore, it was assumed that COX-2 inhibitors
should treat pain but without gastric toxicity [7]. Never-
theless, COX-2 inhibitors have also been associated with
risk of GI toxicity, but the most noticeable risks are those
associated with cardiovascular diseases and renal toxicity
[8,9].
However, these effects have shown to be dose-dependent
and a class effect has not been reported. Celecoxib, at a
dose of 200 mg/day or less, has similar or fewer risks than
those observed for the traditional NSAIDs [6,9,10]. Aceta-
minophen has few risks for cardiovascular or renal com-
plications, although it has a higher risk for liver
complications [4]. In addition, this drug has the lowest
rate for decreasing inflammation [11,12]. Drugs such as
naproxen and ibuprofen have a higher analgesic and anti-
inflammatory effect, but the risk of GI bleeding is
increased, events that markedly increase medical care
costs [8]. These drugs carry a certain risk for cardiovascular
disorders; however, it is not unacceptable, especially with
the use of naproxen [13].
When NSAIDs such as naproxen and ibuprofen were com-
pared to coxibs, it was observed that both drugs signifi-
cantly decreased pain in percentages similar to those
observed in patients randomized to choice of drug; how-
ever, differences were noteworthy in regard to coxibs with
shorter time until pain relief as well as the control of dys-
peptic-type GI complications in up to 15% [14] and up to
50% in peptic ulcer perforation-like GI complications
[15,16]. All this led the American Pain Society to place
coxibs as the first-choice drugs for the initial treatment of
joint pain in OA regardless of its higher cost as compared
to nonselective NSAIDs [17].
Some economic evaluation studies already published
have attempted to estimate OA care costs. In a study pub-
lished in the U.S. in 1998, it is mentioned that medical
care costs for this disease, from the viewpoint of service
suppliers, range from $5000 to $6000 dollars/patient-
years, depending on patient age and on disease evolution
[18]. In Canada, a study was published that reported
mean annual health care costs per patient for 1999 and
these were estimated at $2456 Canadian dollars [19].
Moreover, in Italy, in a 1-year study, mean cost per patient
was estimated only considering direct costs at~934 Euros
[20]. An important cause for the increase in health care
costs for patients with OA is the treatment of adverse
events associated with the use of nonselective NSAIDs. It
has been consistently documented that medical consulta-
tions, need for hospitalizations and, many times, the use
of concomitant drugs are increased. Therefore, from a
cost-effectiveness viewpoint, the use of coxibs in this
group of patients is very attractive. It was observed that the
use of coxibs, instead of nonselective NSAIDs, in the
group of patients with high-risk OA, substantially
decreased incremental cost-effectiveness ratio from
$275,809 USD to $55,803 USD per each QALY (quality-
adjusted life years) saved [21].
In a developing country such as Mexico with low
resources for drug acquisition and care for drug-related
complications [22,23], it is essential to conduct cost-effec-
tiveness assessment not only to compare costs of two or
three drugs, but also to evaluate drug side effects. It is
important to point out that the IMSS covers the health
needs of 39% of the Mexican population [23] and is
divided into three levels of health care: (1) family medicalCost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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care; (2) specialist care and hospitalization, and (3) diffi-
cult-to-control and complex diseases that demand a
higher degree of medical specialization [24,25].
IMSS uses acetaminophen, nonselective NSAIDs
(diclofenac, naproxen, piroxicam), and celecoxib
(cyclooxygenase-2 inhibitor) for the treatment of pain
due to OA. Thus, the primary consumer of the informa-
tion will be the Institution itself through its operational
staff. A description of medical practice based on the use of
resources for treatment of OA and its cost within the same
Institution will be performed. Currently, these types of
evaluations are a priority for Social Security institutions in
developing countries [26].
The objective of this study was to identify the most cost-
effective, first-choice pharmacological treatment for the
control of joint pain secondary to OA of the knee and/or
hip in patients treated at the IMSS.
Methods
Decision Tree Model
The study constructed an analytical model that may repro-
duce and simplify the clinical reality observed in patients
with OA treated with alternatives compared with the treat-
ment of joint pain at the IMSS. The proposed model
aimed to identify the probability to control pain among
the different therapies as well as the potential develop-
ment of GI, renal and/or cardiovascular complications
during a 6-month time horizon. The clinical significance
of adverse drug events leads us to recognize them as an
acute situation. When they occur, an action is generated.
In the case of study alternatives, the action may be to
administer concomitant treatment or drug discontinua-
tion. In this way, none of these events should occur again
in the same subject. Thus, it is not possible to describe the
phenomenon as a series of observational cycles but as a
group of events occurring as one being a consequence of
another. Therefore, we considered that the best descriptive
analysis was the decision tree model.
The model starts with the description of a base case of an
adult patient diagnosed with OA of the knee and/or hip
and the need for pharmacological treatment for severe
joint pain. Three decision nodes corresponding to the
three alternatives (acetaminofen, nonselective NSAIDs or
celecoxib) are generated. The first probabilistic node cor-
responding to pain improvement or no pain improve-
ment arises from each of them. The "no improvement"
branch corresponds to therapeutic failure and the pre-
scription of one of the two remaining alternatives availa-
ble is mandatory, with a new generation of branches, pain
control or no pain control. From the latter, another
branch arises now using the remaining treatment option.
The next tree branch, as a consequence of pain improve-
ment, is divided into the presence of adverse effects or no
adverse effects. When no adverse events occur, it is con-
verted into a terminal node and is considered a therapeu-
tic success, thus corresponding to the effectiveness
measure. The next probabilistic node arises from the
occurrence of adverse events towards the probability for
the development of gastric symptoms, GI bleeding, renal
toxicity, and cardiovascular events during a 6-month
period of continuous treatment with these drugs. A sche-
matic flow chart is shown in Figure 1.
Medication
Considering the scenario of a patient with severe joint
pain secondary to knee and/or hip OA, a comparison of
the costs generated by medical care of patients with OA
receiving any of the three possible treatment alternatives
was proposed; these alternatives were based on IMSS Drug
Formulary and international guidelines [4,27]: celecoxib,
200 mg twice daily; non-selective NSAIDs (naproxen 500
mg, twice daily; diclofenac, 100 mg twice daily; and pirox-
icam 20 mg/day), and acetaminophen 1000 mg twice
daily. Treatment was provided for 6 months.
Direct medical costs and clinical effects of patients treated
with any of the study treatment alternatives were esti-
mated in order to identify the differences among them
and to obtain an incremental cost-effectiveness ratio
(ICER), integrating the values obtained from the study to
the following formula (18,20):
Thus, ICER was obtained by dividing total net costs (incre-
mental costs) between the total net effectiveness (incre-
mental effectiveness) for two alternative treatments (A
and B), in this case, two drugs (nonselective NSAIDs vs.
celecoxib; acetaminophen vs. celecoxib).
Effectiveness measure used for this evaluation was the
number of patients with pain control and no adverse
events per each 1000 patients treated with any of the study
alternatives.
Transition
In order to identify data used to feed the proposed model,
a qualitative systematic literature review was conducted
with the following objectives: 1) to identify the probabil-
ity of developing any of the possible clinical results (pain
control or no pain control) after using one of the drugs
proposed as alternatives for this evaluation for OA treat-
ment, 2) to identify the probability of the occurrence of
serious adverse events with any of the alternatives com-
pared.
ICER
Total tsA Total tsB
EffectivenessA EffectivenessB
=
−
−
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In this study, the QUORUM (quality of reporting of meta-
analyses) recommendations were followed http://
www.consort-statement.org/?o=1065; the aspects not
mentioned were not realized. Search strategy planned for
the systematic review was through electronic databases:
Ovid-Medline, Elsevier-Science Direct, Proquest, Ebsco-E-
Journal Services and Interscience. With the following key
words: "randomized clinical trial", "arthrosis",
"celecoxib", "naproxen", "diclofenac", "piroxicam",
"acetaminophen", "response rate", "safety", "peptic
ulcer", "minor bleed", "major bleed", "nephrotoxicity",
"cardiovascular events" identified in any field only in clin-
ical trials published between 1994 and 2004, in English or
Spanish. For searching clinical results information, only
randomized clinical trials where study intervention was
"celecoxib", "naproxen", "diclofenac", "piroxicam" or
"acetaminophen" in adult patients with OA and where
results were reported as the percentage of patients with
joint pain control, as well as description of rate of adverse
events, were included. Only studies where the first treat-
ment scheme for pain control was administered with one
of the alternatives included in this investigation were con-
sidered.
Sixty clinical trials showing treatment efficacy and/or
safety were identified. Due to the great variety of efficacy
definitions, only those from studies with results expressed
as clinical improvement, whether through a scale or with
a percentage of joint pain improvement, were selected.
Studies evaluated only knee and/or hip pain [28]. Ade-
quate pain control was defined as a 50% change between
baseline and results obtained after the administration of
the study drug as shown by Ta et al. [29].
Only two studies with at least 12 weeks of follow-up were
included, and it was assumed that pain control probabil-
ity remained constant during the 6-month study period.
Celecoxib effectiveness was obtained in six clinical trials
[29-34]. Two were compared vs. acetaminophen, three vs.
naproxen and two vs. lumiracoxib, with sample sizes
between 70 and 1684 patients. To identify the effective-
ness of the nonselective NSAID group, the three studies
evaluating naproxen compared to celecoxib were used
and one clinical trial measuring piroxicam efficacy [33]
was added, the latter compared to meloxicam. For aceta-
minophen effectiveness estimation, two clinical trials
Decision tree Figure 1
Decision tree. Reproduction of clinical reality observed in patients with osteoarthritis (OA) receiving one of the alternatives 
to be compared for the treatment of joint pain, found in each of the three health care levels at the Instituto Mexicano del Seg-
uro Social, identifying the probability to control pain, as well as the development of gastrointestinal, renal and/or cardiovascular 
complications. NSAIDs, nonsteroidal anti-inflammatory drugs; GI, gastrointestinal.Cost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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were identified, PACES (acetaminophen of celecoxib effi-
cacy studies) [32] and another comparing to placebo and
diclofenac [35]. Rate of adverse events was also reported
in these studies.
Probabilities of gastric, renal, and cardiovascular adverse
events, both for celecoxib and the nonselective NSAID
groups, were obtained from two large studies, CLASS
(Celecoxib Long-term Arthritis Safety Study) [36] and
TARGET (Therapeutic Arthritis Research and Gastrointes-
tinal Events Trial) [37,38].
Effectiveness and probabilities for adverse events were
also supported based on several systematic reviews pub-
lished during the period the study was conducted [39-41].
With all the information, efficacy data for joint pain con-
trol and the probabilities to develop severe adverse events
were obtained (Tables 1 and 2) [29-41].
The drug reported with the highest efficacy for the treat-
ment of knee and/or hip OA is celecoxib, followed by any
of the nonselective NSAIDs and, ultimately, acetami-
nophen.
Use of resources and cost estimation
Patients attending the first level of health care are treated
by specialists in family medicine or by general practition-
ers with several years of clinical experience. If a patient
cannot control his/her symptoms, he/she is referred for
evaluation by a specialist in a Hospital General de Zona
(HGZ) which, in general, is a rheumatologist or an
internist. Finally, and in more advanced stages of the dis-
ease, the patient is treated by an orthopedic surgeon in a
third-level orthopedic-traumatology hospital. If serious
adverse events occur, these are treated by different special-
ists: peptic symptoms by a gastroenterologist, GI bleeding
as an acute event is treated by the emergency services of
the HGZs and, if patients need to be hospitalized, by gas-
troenterologists and/or internists. In the case of adverse
renal events, patients are treated by nephrologists at the
HZG and, for cardiovascular events, by cardiologists from
the second- and third-level health care institutions.
Identification of the resource use pattern was made
through the description of a series of type cases, which
describe the average patient in each of the tree branches
(the three tree branches are based on type of drug used for
treatment (Figure 1) and through the experts' opinion, the
type of medical resources to be used for his/her medical
care was obtained. The group of consensus experts was
integrated by 18 family doctors, 5 gastroenterologists, 5
internists, 4 specialists in medical/surgical emergencies, 3
nephrologists, 3 cardiologists, 5 rheumatologists and 10
orthopedists working at the third level of health care.
According to their specialty, all described the use of
resources for patients with OA. This information was
complemented with the review of clinical files to estimate
costs for complications within the institutional setting (n
= 120).
Unit costs for each resource used were identified in order
to estimate an expected mean total cost. Estimation of the
use of resources for patients not presenting adverse events
was performed by family doctors, rheumatologists and
orthopedists.
Estimation was done for the use of resources for medical
care due to adverse events. In the case of GI events, special-
ists in medical/surgical emergencies, internists and gastro-
enterologists were interviewed. For nephrotoxicity
treatment, nephrologists were consulted, and for the
description of the resource use pattern in the case of cardi-
ovascular events, cardiologists were interviewed. Each spe-
cialist must have proven that he/she was working at the
IMSS with clinical experience of at least 5 years and certi-
fication issued by the corresponding specialty board.
These physicians did not know the study hypothesis.
Information on the time of use, type and amount of drugs
used, number and type of laboratory tests performed dur-
ing ambulatory treatment and/or hospitalization, number
of inter-consultations with other services, and number
and type of surgical interventions were obtained for each
case type.
Table 1: Efficacy probability data for joint pain control in patients with OA
Drugs Pain control Presence of adverse events References
Celecoxib 0.6540 0.567 [29-34]
Nonselective NSAIDs 0.6091 0.45 [29-31]
Acetaminophen 0.515 0.68 [32,35]
OA, osteoarthritis; NSAIDs, nonsteroidal anti-inflammatory drugs.
Effectiveness measure used for this evaluation was number of patients with pain control and no adverse events.Cost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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Costs for each resource identified were obtained from sev-
eral information sources. Unit prices for laboratory and
imaging tests were identified through the Planning and
Finance Department at the Hospital de Traumatología y
Ortopedia: Unidad Médica de Alta Especialidad "Dr. Victorio
de la Fuente Narváez"; moreover, IMSS official unit costs
published in the Diario Oficial were identified [42]. Prices
of drugs used in medical interventions at the IMSS were
obtained from the Institute Web site [43].
Time Horizon
Research time horizon was 6 months, similar to other
studies [44,45]. During this time period intertemporal
preferences of physicians and/or patients were not
expected to change; thus, discount rates were not applied
in the investigation.
Sensitivity Analysis
A one-way sensitivity analysis was conducted to deter-
mine the minimum values needed to have the most cost-
effective option to control joint pain. Sensitivity analysis
also aimed to identify result robustness; thus, changes in
some initial assumptions were made to observe if conclu-
sions were maintained towards the same direction. There-
fore, a probabilistic sensitivity analysis was conducted to
introduce a certain level of uncertainty using a first-order
Monte Carlo simulation that allowed the identification of
potential variation both in costs and effectiveness and to
observe their dispersion levels. Probabilistic sensitivity
analyses used triangular distributions of costs (dispersion
obtained from the hospital records) and effectiveness.
Finally, with the same simulation, the net economic ben-
efits (NEB) analysis was conducted. NEB is an analysis
that describes the uncertainty in the incremental effective-
ness and cost values. Economic benefits may also be
understood as the profits an institution may obtain for
using a particular treatment. The NEB has the following
formula:
where economic benefits for treatment A are obtained
from the difference between mean effectiveness measure
(μE) multiplied by the willingness of the healthcare insti-
tution to pay (λ) and mean costs (μC) for such alternative
(44-46-48).
The project was carried out according to IMSS investiga-
tion regulations and was approved by the IMSS Health
Coordination Ethics and Investigation Committee (No.
2005-785-142). In order to perform the economic assess-
ment, the authors used the software Tree Age 2007 (Cop-
yright© 1988–2007 by TreeAge Software, Inc. All rights
reserved. Williamstown, MA).
Results
Costs
Health care costs for one patient in the first level of care
during a period of six months is, on average, $2,388.59
Mexican pesos (MXP) [1 USD = 10.00 MXP (September
2008)]. This includes a consultation for diagnosis and
three follow-up consultations, along with the following
laboratory tests: hematology, C-reactive protein, rheuma-
toid factor, determination of uric acid concentration and
one chest x-ray. A nonselective NSAID was prescribed and,
if there was no response, acetaminophen was then added.
When gastric symptoms were present, a histamine h-
receptor antagonist such as ranitidine was added or the
patient was referred to the second-level of care for evalua-
tion. To keep simple, cost compounds are not specified
for each procedure (adverse events).
In the case of second-level care during a 6-month treat-
ment period for a patient with no adverse effects, the esti-
mated cost was $2,165.15 MXP. This includes a diagnostic
consultation by a rheumatologist, which implies one
chest x-ray as well as three follow-up consultations and
administration of initial treatment. In this case, acetami-
nophen is used and, if no response is achieved, a nonse-
lective NSAID is prescribed.
As far as third level health care concerns, health care costs
for the 6-month period is, on average, $5,051.84 MXP
(Figure 2). This includes two medical consultations, one
NBAE C AA =∗ − μλ μ
Table 2: Severe adverse event probabilities
Drugs Peptic symptoms GI bleeding Adverse cardiovascular events Nephrotoxicity
Celecoxib 0.50 0.0046 0.0039 0.0069
Nonselective NSAIDs 0.618 0.0136 0.0047 0.009
Acetaminophen 0.343 0 0 0
NSAIDs, nonsteroidal anti-inflammatory drugs.
References 29–35 were used for data.Cost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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chest X rays, determination of clotting time and urinalysis.
Generally, patients are treated with a cyclooxygenase-2
inhibitor.
The highest cost generated for OA treatment was for med-
ical consultation except for the third level where the cost
of the drug is higher than the cost of medical consulta-
tions (Figure 2). When assessing adverse events, costs for
treatment of peptic symptoms were $5,800.36 MXP dur-
ing the 6-month study period. This included two medical
consultations, one hematology test, one endoscopy, and
continuous treatment with ranitidine and aluminum and
magnesium gel (Figure 3).
The cost for GI bleeding associated with the use of drugs
was $37,282.82 MXP. This included 1 day at the emer-
gency service and 7 days, on average, of hospitalization as
well as one or two endoscopies, hematology and blood
chemistry. In addition, treatment is initiated with ome-
prazole administered IV and, later on, orally (Figure 3).
Medical care for a patient with serious renal damage was
estimated at $26,998.66 MXP; this included 1 day at the
emergency unit and, on average, 7 days of hospitalization,
laboratory tests: blood chemistry, serum electrolytes, uri-
nalysis, creatinine clearance, one ultrasound along with
management with ASA, diuretics and antihypertensive
agents such as angiotensin converter enzyme inhibitors
(ACEI). For the case of cardiovascular events (CVE), data
obtained for the IMSS came from the study conducted by
Mould et al. [46]. Mean cost for myocardial infarction was
$110,552.00 MXP and for cerebrovascular accident it was
$52,671.00 MXP.
Cost-effectiveness Analysis
The OA drug with the lowest cost, considering the possi-
bility and treatment of adverse events, was celecoxib
($6,524.6 MXP/patient during 6 months of treatment),
although differences are not that significant with the use
of nonselective NSAIDs, but they are with the use of aceta-
minophen. As far as effectiveness is concerned, the drug
with the largest number of patients with pain control
without developing adverse events is again celecoxib, fol-
lowed by nonselective NSAIDs and, ultimately, acetami-
nophen (Table 3). When integrating both measures (costs
and effectiveness) within the deterministic analysis, it is
observed that celecoxib is superior to the other two
choices, with a lower cost and higher effectiveness.
One-way sensitivity analysis
For this type of analysis, it was decided to hypothetically
vary the effectiveness of the alternatives compared in this
Cost components for treating patients with OA at the Instituto Mexicano del Seguro Social Figure 2
Cost components for treating patients with OA at the Instituto Mexicano del Seguro Social. UMF, Family Medi-
cine Unit (Unidad de Medicina Familiar); HGZ: General Hospital (Hospital General de Zona); HTO: Orthopedic and Trauma-
tology Hospital (Hospital de Traumatología y Ortopedia).Cost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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investigation in such a way that the best option
(celecoxib) is no longer cost-effective (Tables 4 and 5).
In this case, celecoxib would have to decrease it effective-
ness for joint pain treatment up to 44% and, for control
with no adverse events, up to 41% in order not to be any
longer the most cost-effective option of the compared
alternatives. Nonspecific NSAIDs would have to increase
their effectiveness up to 67.5% for pain control and up to
49.5% for pain control without the presence of adverse
events to be the most cost-effective option using the defi-
nition of extended dominance. To be absolute, NSAIDs
would have to increase their effectiveness up to 82.5% for
pain control and 63.0% for pain control without the pres-
ence of adverse events (for extended dominance defini-
tion see Table 5). In the case of acetaminophen, it would
need to obtain an absolute dominance just for pain con-
trol with an effectiveness of 55%, but for pain control with
no adverse events its efficacy would have to increase up to
94%, but only to reach an extended dominance.
Probabilistic sensitivity analysis
For conducting the probabilistic sensitivity analysis, a
hypothetical cohort of 10,000 samples using the first-
order Monte Carlo method was previously simulated.
With this simulation, it is expected to have a significant
Mean cost for OA treatment according to different scenarios and to each adverse event at the Instituto Mexicano del Seguro  Social Figure 3
Mean cost for OA treatment according to different scenarios and to each adverse event at the Instituto Mexi-
cano del Seguro Social. GI, gastrointestinal.
Table 3: Incremental cost-effectiveness analysis (direct medical costs and clinical effects of patients treated with alternatives 
therapies)
Treatments Costs* Costs ▲† Effectiveness‡ Effectiveness▲ ACER** ICER††
Celecoxib 6,524.6 371 17.595
Nonselective NSAIDs 6,587.4 62.8 274 97 24.033 Dominance
Acetaminophen 7,026.7 502.1 270 101 26.029 Dominance
*Estimated costs by patient (Mexican pesos).
†Incremental costs.
‡Number of patients with pain control without adverse events.
**Average cost-effectiveness ratio.
††Incremental cost-effectiveness ratio.
NSAIDs, nonsteroidal anti-inflammatory drugs.Cost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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number of measures that allow estimation of the variabil-
ity magnitude due to chance, both for costs and effective-
ness. With this data, it is possible to construct
acceptability curves for each treatment. These curves dem-
onstrate the probability for a treatment to be cost-effec-
tive, depending on the willingness to pay by the
healthcare institution. Figure 4 shows the acceptability
curves for the three alternatives for joint pain due to OA.
It may be observed in this plot how celecoxib is the most
cost-effective option in 45% of cases, regardless of willing-
ness to pay. Nonspecific NSAIDs are cost-effective at a
35% rate and acetaminophen at 20%.
When estimating the NEB, it is observed that higher sav-
ings for the institution may be obtained with celecoxib,
regardless of willingness to pay (Figure 5), followed by
nonspecific NSAID treatment and similarly with acetami-
nophen. There are no significant differences between the
latter two drugs.
In conclusion, the sensitivity analysis stated that, regard-
ing the one-way analysis, celecoxib would be the most
cost-effective option unless it has a marked decrease in its
effectiveness or the other alternatives would have to sig-
nificantly increase their effectiveness. In the probabilistic
analyses, both in the construction of the acceptability
curves and in the estimation of NEBs, celecoxib will
remain as the most cost-effective option compared to the
other two alternatives for the treatment of joint pain due
to OA of the knee and/or hip at the IMSS.
Discussion
Through this cost-effectiveness analysis, it has been
shown that celecoxib was superior to nonspecific NSAIDs
and acetaminophen. There was a lower use of resources
with this type of treatment, especially due to a lower rate
of adverse events, resulting in a decrease in health care
costs. Such results did not change when a probabilistic
sensitivity analysis was performed. Thus, currently it may
be considered that this is the best treatment alternative for
the IMSS.
This investigation conducted an economic evaluation
considering both health results and the cost for medical
Table 4: Probabilistic sensitivity analysis with first-order Monte Carlo simulation
Drugs Mean ± SD* Median Interquartile range
5% 95%
Celecoxib
Cost 6,198.7 ± 15,507.1 5,016.6 3,653.1 10,795.3
Effectiveness 365.0 315.0 125.0 452.0
Nonselective NSAIDs
Cost 6,528.2 ± 6,199.9 5,300.0 2,340.7 14,497.9
Effectiveness 289.0 265.0 84.0 396.0
Acetaminophen
Cost 6,994.3 ± 46,583.7 5,721.5 2,292.7 15,994.9
Effectiveness 275.0 259.0 74.0 351.0
*Standard deviation.
Costs are expressed in Mexican pesos and effectiveness is according to number of patients with pain control without adverse events.
NSAIDs, nonsteroidal anti-inflammatory drugs.
Table 5: One-way sensitivity analysis (minimum values in order to be the most cost-effective option to control joint pain)
Type of dominance
Extended* Absolute
Celecoxib
Control joint pain ↓ 44.0%
Control joint pain without adverse events ↓ 41.0%
Nonselective NSAIDs
Control joint pain ↑ 67.5% 82.5%
Control joint pain without adverse events ↑ 49.5% 63.0%
Acetaminophen
Control joint pain ↑ 48.0% 55.0%
Control joint pain without adverse events ↑ 94.0% it is not feasible
NSAIDs, nonsteroidal anti-inflammatory drugs.
Extended dominance is defined as the set of all possible mixed therapeutic strategies that dominates a unique strategy in both higher effectiveness 
and less cost [67].Cost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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care associated with the use of cyclooxygenase-2 inhibi-
tors, nonspecific NSAIDs, and acetaminophen. In the case
of the effectiveness analysis, through the systematic
review, some important differences were found, especially
when defining an effectiveness measure as pain control
with no adverse events. In other economical evaluation
models, it was assumed that pain control effectiveness was
the same and that there were differences only in the fre-
quency of adverse events [47-49]. In this study we were
more specific with the effectiveness measure, making the
differences among drugs more evident.
In the present research the pain control without adverse
events in OA patients was used as an effectiveness meas-
ure. In addition, it is important to mention that all the
clinical trials which include NSAIDs, acetaminophen and
celecoxib in the management of OA are mainly focus in
pain control [13,45,50-52]; In this sense, this economic
evaluation is in line with the effectiveness measure com-
mon used in the literature. Nevertheless, our assessment is
leaving out what other authors employed as a complete
evaluation for the treatment of OA which include the pain
control but also the affected articulation functions [53].
When conducting the complete cost-effectiveness analy-
sis, the results of this study are similar to other models
published [44,47-49] where the use of the drug from the
cyclooxygenase-2 inhibitors group is the most cost-effec-
tive. An important issue to be mentioned is that this
model included the probability to develop, within the 6
months of treatment, cardiovascular and nephrotoxicity
events associated with non-specific NSAIDs, which is dif-
ferent from other models where only gastrointestinal
events (peptic and/or digestive tract bleeding) were con-
sidered [45]. The studies encouraging the launching of
rofecoxib into the market based their rationale mainly on
the presence of cardiovascular events [54-57]. In the case
of celecoxib, very low frequencies for the development of
this type of event during the time specified for this study
were estimated (in the systematic review); in fact, they are
similar for the non-specific NSAIDs group, which is con-
sistent with the recent FDA recommendations [58] on the
use of these types of drugs during short periods of time. A
recent systematic review confirms this assumption, where
the RR for cardiovascular events with celecoxib was 1.06
(95% CI 0.91–1.23) and with naproxen it was 0.97 (95%
CI 0.87–1.07) [54]. A meta-analysis showed similar
results with an RR for vascular events of 1.60 (95% CI
0.90–2.9) with celecoxib and 0.92 (95% CI 0.67–1.26)
for naproxen [13]. Another meta-analysis, which shows
only non-specific NSAIDs findings, reported an RR for
acute myocardial infarction of 0.99 (95% CI 0.88–1.11)
with naproxen, and they did not evaluate celecoxib. It has
been mentioned that the risk for cardiovascular events is
similar between celecoxib and naproxen [50].
In a meta-analysis of clinical trials published up to June
2006, including 37 studies evaluating celecoxib, a RR of
0.61 (95% CI 0.40–0.94) for renal impairment and 0.83
(95% CI 0.71–0.97) for hypertension was shown [9]. In
another study published at the end of 2007, a RR for acute
renal impairment of 2.00 (95% CI 1.32–3.04) and 1.33
(95% CI 0.94–1.88) for celecoxib at doses >200 mg/day
and <200 mg/day, respectively, was reported. With the use
of naproxen, a RR of 3.62 (95% CI 2.01–6.53) and 1.65
(95% CI 0.88–3.08) at a dose >750 mg/day and <750 mg/
day, respectively, was reported. This confirmed that the
drug with the lowest risk was celecoxib, especially at a
dose of 200 mg/day or less [6]. In a recent study it was
confirmed that the drug that had less risk to suffer from a
hospitalization for gastrointestinal bleeding was the
celecoxib [59]
Cost-effectiveness acceptability curves for the decision con- cerning the most efficient management of OA at the Instituto  Mexicano del Seguro Social Figure 4
Cost-effectiveness acceptability curves for the deci-
sion concerning the most efficient management of 
OA at the Instituto Mexicano del Seguro Social.
Net economic benefits for joint pain treatment due to OA at  the Instituto Mexicano del Seguro Social Figure 5
Net economic benefits for joint pain treatment due 
to OA at the Instituto Mexicano del Seguro Social.Cost Effectiveness and Resource Allocation 2008, 6:21 http://www.resource-allocation.com/content/6/1/21
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One limitation of this study is that the systematic review
included only articles published; thus, a possibility of a
publication bias cannot be ruled out. On the other hand,
the reports of the clinical trials included in the study do
not necessarily reflect the results that would be obtained
in the Mexican population because other factors modify-
ing local clinical response may exist. The probabilities
feeding the model were obtained from publications from
1994 to 2004, probabilities that may have changed with
current data.
Regarding the estimations for the use of resources, they
represent only local clinical practices; thus, external valid-
ity would be compromised only to similar practices. Nev-
ertheless, it may be stated that this model is a good
approximation and provides an idea of what would hap-
pen in the reality of the IMSS, and other health care sys-
tems in developing countries.
Regarding the time horizon, this assessment is in line with
the reported timelines used by other researchers in the lit-
erature, specially the time needed to control the articular
pain [45]; it is honest to say that with the timeline
employed in our study it was not feasible to assess neither
compliance nor long-term adverse events. Although,
healthcare costs estimations and presence of side effects
have been reported mainly for this time horizon within
the literature [45].
OA is a disease with a trend towards a high prevalence
[1,514, [60-62]] because it is strongly associated with
aging, among other factors. With the demographic and
epidemiological transition [63] in developing countries,
health systems face a high demand for medical services
[26,64]. Within a low-resource environment, it is impor-
tant for decision makers to efficiently choose the use of
available resources, a reason why economic evaluation
analyses are important when making the selections
[22,23,26].
According to our knowledge, this is the first analysis of
this type carried out in a developing country. IMSS is a
prototype for health institutions that aim to provide social
security to the population and shares many common
characteristics with other social security institutions in
other developing countries [65]. In developing countries,
it has been considered that the priority for investigation is
the one allowing decision makers to more clearly under-
stand how health care resources should be used [66]. This
type of study provides an answer to this need, and it can
be pointed out that, in countries where the social security
system is distributed such as the IMSS and organized
according to the levels of care previously mentioned,
results may be extrapolated to them.
Conclusion
The least expensive drug for the treatment of knee and/or
hip OA, considering the possibility and treatment for
adverse events, was celecoxib ($6,524.6 MXP per patient
during 6 months of treatment), in addition to it being the
most effective treatment.
With this analysis, it may be stated that the use of cycloox-
ygenase-2 inhibitors, such as celecoxib, is the treatment
with the best cost-effective results (lowest mean cost-effec-
tiveness ratio $17.5 MXP/patient), which may result in a
lower use of resources due to the presence of adverse
events related to drugs for treating OA and the consequent
cost decrease.
Within the sensitivity analysis, it may be pointed out that
regarding the univariate analysis, celecoxib would have to
markedly decrease its effectiveness, or the other alterna-
tives would have to increase significantly. On the other
hand, in the probabilistic analysis, both in the construc-
tion of the acceptability curves and in the estimation of
net economic benefits, the most cost-effective option
remains to be celecoxib, compared to the other two alter-
natives for the treatment of knee and/or hip joint pain at
IMSS.
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